⏳ Fetching live dividend data...
Home › Calculator › NGM Dividend Calculator 2026
NGM Biopharmaceuticals, Inc. · NASDAQ
Price: $1.54 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in NGM → $9551727465781.72M in 10 years · $795,379,200,939,437,000.00/month
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open NGM position with:
Real after-tax yield depends on where you live and how you hold NGM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 129.87% | 127.07% | $12,987 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 110.39% | 107.59% | $11,039 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 103.90% | 101.10% | $10,390 / yr |
| 🇬🇧 UK ISA | 0% | 129.87% | 127.07% | $12,987 / yr |
| 🇬🇧 UK Taxable | 8.75% | 118.51% | 115.71% | $11,851 / yr |
| 🇨🇦 TFSA | 0% | 129.87% | 127.07% | $12,987 / yr |
| 🇨🇦 CA Taxable | 25% | 97.40% | 94.60% | $9,740 / yr |
| 🇦🇺 Super (pension) | 15% | 110.39% | 107.59% | $11,039 / yr |
| 🇦🇺 AU Taxable | 30% | 90.91% | 88.11% | $9,091 / yr |
| 🇩🇪 DE Taxable | 26.375% | 95.62% | 92.82% | $9,562 / yr |
| 🇫🇷 FR Taxable | 30% | 90.91% | 88.11% | $9,091 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
NGM pays quarterly — 4 times per year. Next ex-div: TBD.
How NGM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for NGM sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| J-Other | 2024-04-05 | 1,000 | — | — | ||
| D-Return | 2024-04-05 | 44,000 | — | — | ||
| J-Other | 2024-04-05 | 1,000 | — | — | ||
| D-Return | 2024-04-05 | 44,000 | — | — | ||
| J-Other | 2024-04-05 | 1,000 | — | — | ||
| D-Return | 2024-04-05 | 44,000 | — | — | ||
| J-Other | 2024-04-05 | 1,000 | — | — | ||
| D-Return | 2024-04-05 | 100,000 | — | — | ||
| D-Return | 2024-04-05 | 24,000 | $13.35 | $320.4K | ||
| D-Return | 2024-04-05 | 19,619 | $17.24 | $338.2K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the NGM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
NGM Biopharmaceuticals, Inc. (NGM) is currently trading at $1.54, 95% below its 52-week high. The current dividend yield is 129.87% based on an annual payout of $2.00 per share.
NGM Biopharmaceuticals, Inc. (NGM) is a healthcare stock currently trading at $1.54 with a dividend yield of 129.87%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever